1388893-75-1

Upstream product

• 1031289-75-4 (1r,4r)-1-N,1-N-dimethylcyclohexane-1,4-diamine dihydrochloride 
• 204580-28-9 2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-N-methyl-ethanamine 
• 1388893-61-5 C₁₉H₂₆N₄O₂S*ClH 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 1388893-60-4 C₂₀H₂₈N₄O₂S 
• 1388893-59-1 C₁₉H₂₅N₅S 
• 1388893-58-0 C₁₈H₂₅ClN₄S 
• 1388893-57-9 C₁₈H₂₆N₄OS 
• 1388893-56-8 C₂₀H₂₈N₄O₂S 
• 1019014-42-6 C₁₂H₁₁ClN₂O₂S 
• 1019014-34-6 ethyl 12-hydroxy-7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraene-3-carboxylate 

Downstream Products

• 1388893-74-0 2-(12-[[4-(dimethylamino)cyclohexyl]amino]-7-thia-9,11-diazatricyclo[6.4.0.0[2,6]]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-3-yl)-N-(2-hydroxyethyl)-N-methylacetamide 

Relevant academic research and scientific papers

IRAK INHIBITORS AND USES THEREOF

The present invention provides thieno[2,3-d]pyrimidine derivative compounds, and pharmaceutical compositions thereof. The invention also includes methods inhibiting an IRAK protein kinase in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. The invention also includes methods of treating an IRAK-mediated disorder, disease, or condition in a patient by administering the thieno[2,3-d]pyrimidine derivative compound.

IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.